Plasma ACE2 Activity is an Independent Prognostic Marker in Chagas' Disease and Equally Potent as BNP

Wang, Yong; Moreira, Maria da Consolação Vieira; Heringer-Walther, Silvia; Ebermann, Linda; Schultheiss, Heinz‐Peter; Wessel, Niels; Siems, Wolf‐Eberhard; Walther, Thomas

doi:10.1016/j.cardfail.2009.09.005

Cited by 45 publications

(60 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the human population, genetic variability in the ACE2 gene correlates with susceptibility to cardiovascular disease. In human heart failure, plasma ACE2 activity is increased and correlates with adverse clinical outcomes [23,40]. The expression of ACE2 shows a dramatic decrease with aging independent of gender [41].…”

Section: Biochemical Aspects Of Ace2mentioning

confidence: 99%

Role of ACE2 in diastolic and systolic heart failure

et al. 2011

View full text Add to dashboard Cite

A novel angiotensin-converting enzyme (ACE) homolog, named ACE2, is a monocarboxypeptidase which metabolizes several peptides. ACE2 degrades Angiotensin (Ang) II, a peptide with vasoconstrictive/proliferative effects, to generate Ang-(1-7), which acting through its receptor Mas exerts vasodilatory/anti-proliferative actions. In addition, as ACE2 is a multifunctional enzyme and its actions on other vasoactive peptides can also contribute to its vasoactive effects including the apelin-13 and apelin-17 peptides. The discovery of ACE2 corroborates the establishment of two counter-regulatory arms within the renin-angiotensin system. The first one is formed by the classical pathway involving the ACE-Ang II-AT(1) receptor axis and the second arm is constituted by the ACE2-Ang 1-7/Mas receptor axis. Loss of ACE2 enhances the adverse pathological remodeling susceptibility to pressure-overload and myocardial infarction. ACE2 is also a negative regulator of Ang II-induced myocardial hypertrophy, fibrosis, and diastolic dysfunction. The ACE2-Ang 1-7/Mas axis may represent new possibilities for developing novel therapeutic strategies for the treatment of hypertension and cardiovascular diseases. In this review, we will summarize the biochemical and pathophysiological aspects of ACE2 with a focus on its role in diastolic and systolic heart failure.

show abstract

Section: Biochemical Aspects Of Ace2mentioning

confidence: 99%

Role of ACE2 in diastolic and systolic heart failure

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Nonetheless, ongoing efforts for the identification of additional biomarkers are underway, including electrocardiographic, immunologic and biochemical markers, which may greatly improve and facilitate the monitoring of Chagas disease progression and thus vaccine evaluation. [86][87][88][89][90][91][92] As indicated above, a successful vaccine will need to induce a strong cellular immune response, with the activation of CD8 + cytotoxic T cells in order to effectively control T. cruzi parasites. This requirement places some constraints on the formulations and types of vaccines that may be used, since such a response is harder to induce than a humoral response.…”

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning

confidence: 99%

Advances and challenges towards a vaccine against Chagas disease

Quijano-Hernández

Dumonteil

2011

Human Vaccines

View full text Add to dashboard Cite

“…Ongoing studies have focused on endothelin 1, tumor necrosis factor-α, B-type natriuretic peptide, angiotensin-converting enzyme, and also autoantibodies as candidates for disease prognosis. 23,[25][26][27] Among the last ones, cross-reactive Abs against β1-adrenergic and M2 muscarinic receptors have been associated with different arrhythmogenic anomalies, which may contribute to the distinct cardiac alterations observed in patients with SCC. 28 Although receptor Abs are the result of molecular mimicry with parasite ribosomal P proteins, 29,30 R13, P013, and P0β peptides were not good candidates as serological markers of Chagas disease in this study.…”

mentioning

confidence: 99%

Evaluation of In-House ELISA Using Trypanosoma cruzi Lysate and Recombinant Antigens for Diagnosis of Chagas Disease and Discrimination of Its Clinical Forms

Longhi¹,

Brandariz²,

Lafon³

et al. 2012

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. The aim of this work was to investigate the potential usefulness of Trypanosoma cruzi lysate, recombinant protein JL7, and peptides P013, R13, JL18, JL19, and P0β as serological markers for human Chagas disease. We analyzed 228 sera from Brazilian Chagas disease patients classified into four clinical groups and 108 from non-chagasic patients. We defined the diagnostic sensitivity, specificity, and Kappa index measured by enzyme-linked immunosorbent assay (ELISA). As previously described, the highest values of diagnostic parameters were achieved for T. cruzi lysate and JL7; peptide P013 showed high specificity but low sensitivity. The other peptides resulted in lower sensitivity and specificity in our ELISA than T. cruzi lysate and JL7 protein. Antibodies against JL7 protein were mainly detected in sera from patients with severe chagasic cardiomyopathy, compared with those from the indeterminate form, whereas peptides failed to discriminate between the clinical forms of the disease.Chagas disease, caused by the hemoflagellate Trypanosoma cruzi, is a widespread tropical disease affecting at least 8 million people primarily in Latin American countries.1 The acute phase lasts 1 or 2 months and is usually symptomless, 2 however most of the infected individuals enter a life-long chronic phase with its asymptomatic and symptomatic forms. The asymptomatic, also called indeterminate form is characterized by the absence of clinical symptoms. However,~40% of persons with chronic T. cruzi infection develop symptoms of visceral damage, which may include cardiac lesions, digestive alterations, or both clinical manifestations (cardiac plus digestive). 2In the chronic phase, the primary method for diagnosis is the search of antibodies by serological testing, whereas the secondary diagnostic techniques are parasitological tests.1 So far, conventional serological tests include complement fixation, 3,4 indirect immunofluorescence assay (IFA), 5 indirect hemagglutination assay (IHA), 6 direct agglutination with 2-mercaptoethanol (DA-2ME), 7 and enzyme-linked immunosorbent assay (ELISA). [8][9][10] These tests usually use crude or semi-purified parasite preparations, often derived from a stage present only in the insect and in cultures at 26 C (epimastigote) but absent in the human host. Other assays incorporate more defined parasite components, like multiple fusion proteins containing epitopes from various T. cruzi antigens.11-15 Moreover, a rapid immunochromatographic assay (Chagas Stat-Pak, Chembio Diagnostic Systems, Medford, NY) has also been developed by employing a mixture of T. cruzi recombinant antigens, presenting a different degree of performance. [16][17][18] However, in the absence of a true gold standard, it is still necessary to carry out at least two different serological tests to establish a reliable diagnosis of Chagas disease. Indeed, the World Health Organization (WHO) consensus guidelines recommend to perform a third assay or repeat sampling to confirm or exclude the diagnosis if two serological tests ...

show abstract

Plasma ACE2 Activity is an Independent Prognostic Marker in Chagas' Disease and Equally Potent as BNP

Cited by 45 publications

References 30 publications

Role of ACE2 in diastolic and systolic heart failure

Role of ACE2 in diastolic and systolic heart failure

Advances and challenges towards a vaccine against Chagas disease

Evaluation of In-House ELISA Using Trypanosoma cruzi Lysate and Recombinant Antigens for Diagnosis of Chagas Disease and Discrimination of Its Clinical Forms

Contact Info

Product

Resources

About